Refinement of a Human Challenge Model for Evaluation of Enterotoxigenic Escherichia coli Vaccines
Authors:
Open Access
- 18 August 2011
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 18 (10) , 1719-1727
Abstract
EnterotoxigenicEscherichia coli(ETEC) strain H10407 (serotype O78:H11 producing heat-labile toxin [LT], heat-stable toxin [ST], and colonization factor I [CFA/I]) induces reliably high diarrheal attack rates (ARs) in a human challenge model at doses of ≥109CFU. A descending-dose challenge study was conducted with changes to the standard fasting time and buffer formulation, seeking conditions that permit lower inocula while maintaining reproducibly high ARs. In cohort 1, 20 subjects were fasted overnight and randomized 1:1:1:1 to receive H10407 at doses of 108CFU with bicarbonate, 108CFU with CeraVacx, 107CFU with bicarbonate, or 107CFU with CeraVacx. Subsequent cohorts received H10407 (107CFU with bicarbonate) with similar fasting conditions. Cohort 2 included 15 ETEC-naïve volunteers. Cohort 3 included 10 ETEC-naïve volunteers and 10 rechallenged volunteers. In all, 25/35 (71%) ETEC-naïve recipients of 107CFU of H10407 developed moderate or severe diarrhea (average maximum stool output/24 h = 1,042 g), and most (97%) shed H10407 (maximum geometric mean titer = 7.5 × 107CFU/gram of stool). Only one of 10 rechallenged volunteers developed diarrhea. These rechallenged subjects had reduced intestinal colonization, reflected by quantitative microbiology of fecal samples. Among the 35 ETEC-naïve subjects, anti-lipopolysaccharide (LPS) O78 serum antibody responses were striking, with positive IgA and IgG antibody responses in 33/35 (94%) and 25/35 (71%), respectively. Anti-heat-labile enterotoxin (LTB) serum IgA and IgG responses developed in 19/35 (54%) and 14/35 (40%) subjects, respectively. Anti-CFA/I serum IgA and IgG responses were detected in 15/35 (43%) and 8/35 (23%) subjects. After the second challenge, participants exhibited blunted anti-LPS and -LTB responses but a booster response to CFA/I. This ETEC model should prove useful in the future evaluation of ETEC vaccine candidates.Keywords
This publication has 36 references indexed in Scilit:
- A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC)Vaccine, 2011
- Campylobacter jejuniStrain CG8421: A Refined Model for the Study of Campylobacteriosis and Evaluation ofCampylobacterVaccines in Human SubjectsClinical Infectious Diseases, 2009
- Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and MexicoVaccine, 2007
- Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) diseaseVaccine, 2007
- Immune Response, Ciprofloxacin Activity, and Gender Differences after Human Experimental Challenge by Two Strains of Enterotoxigenic Escherichia coliInfection and Immunity, 2007
- Enterotoxigenic Escherichia coli in Developing Countries: Epidemiology, Microbiology, Clinical Features, Treatment, and PreventionClinical Microbiology Reviews, 2005
- Immunoprotective oral whole cell vaccine for enterotoxigenicEscherichia colidiarrhea prepared by in situ destruction of chromosomal and plasmid DNA with colicin E2FEMS Microbiology Letters, 1988
- Treatment of Experimentally Induced Enterotoxigenic Escherichia coli Diarrhea with Trimethoprim, Trimethoprim-Sulfamethoxazole, or PlaceboClinical Infectious Diseases, 1982
- Prophylactic Doxycycline for Travelers' DiarrheaNew England Journal of Medicine, 1978
- Enterotoxigenic Escherichia coli Isolated from Patients at a Hospital in DaccaThe Journal of Infectious Diseases, 1977